Daily Bulletin

Men's Weekly

.

Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial completed

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
  • Clarity Pharmaceuticals completes recruitment for the initial dosimetry phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCT) in patients with metastatic castrate-resistant prostate cancer (mCRPC).
  • Dosimetry data is being prepared for Safety Review Committee before moving into...

Read more: Recruitment for the dosimetry phase of Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate...

Business News

Tuning Strategies for Modern Trucks: Putting SCT X4 Performance to the Test

The Case for Aftermarket Tuning in Modern Trucks Factory programmers aren't trying to thrill you. They’re chasing emissions compliance, warranty safety nets, and broad market compatibility. That co...

Daily Bulletin - avatar Daily Bulletin

Automotive Expert, Raffy Sgroi, Warns: Australia is Building Snowflakes in the Desert with EV Policy

With the National Electric Vehicle Strategy due for a comprehensive review during 2026, automotive expert and senior government advisor, Raffy Sgroi, warns that Australia is rushing electric vehic...

Daily Bulletin - avatar Daily Bulletin

China Gold Coin Group Launched 2026 Chinese Dragon Silver Bullion Coin at World Money Fair in Berlin

China Gold Coin Group Co., Ltd. unveiled its 2026 Chinese Dragon Silver Bullion Coin at the World Money Fair held in Berlin, Germany, from January 29 to 31. Led by Mr Jinpu Jiao, Chairman of the Boa...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business